Clinical trial readout dates for Nektar Therapeutics, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2028.
| Phase 3 Rezpegaldesleukin Moderate-to-Severe Atopic Dermatitis · NCT07690371 | May 2028 Recruiting |
| Phase 3 Rezpegaldesleukin Moderate-to-Severe Atopic Dermatitis · NCT07711418 | June 2028 Recruiting |
Nektar Therapeutics reported $945M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-13). Its net loss for that quarter was $56M; at that rate the cash would last about 17 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-13 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-12 |